TG Therapeutics (TGTX) & Protagonist Therapeutics (PTGX) Head to Head Review

TG Therapeutics (NASDAQ: TGTX) and Protagonist Therapeutics (NASDAQ:PTGX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Valuation and Earnings

This table compares TG Therapeutics and Protagonist Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
TG Therapeutics $150,000.00 5,934.60 -$78.25 million ($1.93) -6.53
Protagonist Therapeutics N/A N/A -$37.17 million ($2.69) -6.15

Protagonist Therapeutics has lower revenue, but higher earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for TG Therapeutics and Protagonist Therapeutics, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TG Therapeutics 0 0 9 0 3.00
Protagonist Therapeutics 0 0 3 0 3.00

TG Therapeutics currently has a consensus target price of $27.19, indicating a potential upside of 115.77%. Protagonist Therapeutics has a consensus target price of $37.00, indicating a potential upside of 123.56%. Given Protagonist Therapeutics’ higher possible upside, analysts plainly believe Protagonist Therapeutics is more favorable than TG Therapeutics.


This table compares TG Therapeutics and Protagonist Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
TG Therapeutics -73,217.77% -151.21% -116.84%
Protagonist Therapeutics N/A -64.21% -50.51%

Insider and Institutional Ownership

46.9% of TG Therapeutics shares are held by institutional investors. Comparatively, 47.5% of Protagonist Therapeutics shares are held by institutional investors. 16.7% of TG Therapeutics shares are held by insiders. Comparatively, 15.5% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

TG Therapeutics has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of -0.8, meaning that its share price is 180% less volatile than the S&P 500.


Protagonist Therapeutics beats TG Therapeutics on 7 of the 12 factors compared between the two stocks.

TG Therapeutics Company Profile

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn’s disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply